Max Hasmann
Impact in
- Geriatrics and Gerontology top 0.5%
- Sirtuins and Resveratrol in Medicine
- Oncology top 2%
- HER2/EGFR in Cancer Research
- Drug Transport and Resistance Mechanisms
Papers in
- Oncology 29
- HER2/EGFR in Cancer Research 24
- Drug Transport and Resistance Mechanisms 3
- Cancer Cells and Metastasis 2
-
- Sirtuins and Resveratrol in Medicine 2
- Co-authors
- Isabel Schemainda (6 shared papers)Werner Scheuer (4 shared papers)Thomas Friess (4 shared papers)Birgit Bossenmaier (2 shared papers)Helmut J. BURTSCHER (1 shared paper)Josef Endl (1 shared paper)R. Löser (4 shared papers)Benno Rattel (2 shared papers)
- Journals
- Molecular Cancer Therapeutics (4 papers)Clinical Cancer Research (4 papers)Cancer Treatment Reviews (2 papers)Biochemical Pharmacology (2 papers)Pharmaceuticals (1 paper)
- Partner nations
- GermanySwitzerlandUnited Kingdom
In The Last Decade
Max Hasmann
43 papers receiving 2.5k citations
Peers
Comparison fields: 5 of 95
- Geriatrics and Gerontology 414
- Oncology 1k
- Cancer Research 208
- Immunology 161
- Radiology, Nuclear Medicine and Imaging 180
Countries citing papers authored by Max Hasmann
This map shows the geographic impact of Max Hasmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Hasmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Hasmann more than expected).
Fields of papers citing papers by Max Hasmann
This network shows the impact of papers produced by Max Hasmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Hasmann. The network helps show where Max Hasmann may publish in the future.
Co-authors
The 25 scholars most cited alongside Max Hasmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. | 2003 | 566 |
| 2 | 2009 | 503 | |
| 3 | 2013 | 96 | |
| 4 | WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. | 2002 | 85 |
| 5 | 2005 | 83 | |
| 6 | 2005 | 80 | |
| 7 | 2012 | 66 | |
| 8 | 2018 | 64 | |
| 9 | 2018 | 61 | |
| 10 | 2013 | 59 | |
| 11 | 1994 | 58 | |
| 12 | 1989 | 57 | |
| 13 | 2020 | 56 | |
| 14 | Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. | 2006 | 55 |
| 15 | 2007 | 53 | |
| 16 | 2011 | 52 | |
| 17 | 1993 | 48 | |
| 18 | 2018 | 46 | |
| 19 | 1995 | 42 | |
| 20 | 2009 | 42 |
About Max Hasmann
Max Hasmann is a scholar working on Oncology, Geriatrics and Gerontology, Cancer Research, Molecular Biology and Genetics, having authored 46 papers that have together received 2.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (24 papers), Estrogen and related hormone effects (4 papers), Cell death mechanisms and regulation (3 papers), Drug Transport and Resistance Mechanisms (3 papers), Lung Cancer Treatments and Mutations (2 papers), Cancer Cells and Metastasis (2 papers), Biochemical and Molecular Research (2 papers) and Sirtuins and Resveratrol in Medicine (2 papers). The work is most often cited by research in Geriatrics and Gerontology (414 citations), Oncology (1k citations), Cancer Research (208 citations), Immunology (161 citations) and Radiology, Nuclear Medicine and Imaging (180 citations). Max Hasmann has collaborated with scholars based in Germany, Switzerland and United Kingdom. Frequent co-authors include Isabel Schemainda, Werner Scheuer, Thomas Friess, Birgit Bossenmaier, Helmut J. BURTSCHER, Josef Endl, R. Löser, Benno Rattel, Simon P. Langdon and Katja Wosikowski. Their work appears in journals such as Molecular Cancer Therapeutics, Clinical Cancer Research, Cancer Treatment Reviews, Biochemical Pharmacology and Pharmaceuticals.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.